Celgene (CELG), Valeant (VRX), Acadia (ACAD), & Gilead Sciences (GILD) Outlook On Drug Pricing Concerns

How Donald Trump’s stance on drug prices will affect each of BNL Finance covered biotechs: CELG, VRX, ACAD, JAZZ, and GILD.

Posted in Healthcare & Biotech, Members, Stock Ratings, Timely Analysis | Tagged , , , , , , , , , | Leave a comment

Why Acadia Pharmaceuticals (ACAD) Will Get More Than $44 From Pfizer (PFE)

Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma

Posted in Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , , , , | 1 Comment

Acadia Pharmaceuticals Inc (ACAD) Outlook With Lewy Body Dementia & Off Label Nuplazid Use

Acadia Pharmaceuticals’ Nuplazid is reportedly seeing a rise in off label use, specifically With Lewy Body Dementia. That’s great news for ACAD stock.

Posted in BNL Reports, Healthcare & Biotech | Tagged , | 3 Comments

Weekend Blitz: Twitter (TWTR), Fitbit (FIT), ACAD & FNMA Stock

Must know news and stories related to Twitter (NYSE:TWTR), Fitbit Inc (NYSE:FIT), ACADIA Pharmaceuticals (NASDAQ:ACAD), and Fannie Mae or FNMA stock.

Posted in Members, Portfolio Strategy, Weekend Blitz | Tagged , , , , , , , , , | Leave a comment

10 Acquisition Predictions For 2017: FIT, TWTR, ACAD, SKX, DISH

A series that examines 10 acquisition targets in 2017. Furthermore, we identify the companies most likely to acquire FIT, TWTR, ACAD, SKX, & DISH

Posted in BNL Reports, Members, Mergers & Acquisitions | Tagged , , , , , , , , , | Leave a comment

Weekend Blitz: Fitbit (FIT), Amazon (AMZN), Rite Aid (RAD), & NOK Stock

Big news announcements & stories related to Fitbit (FIT), Rite Aid (RAD), Amazon.com (AMZN), ACADIA Pharmaceuticals (ACAD), and Nokia Corp, or NOK stock.

Posted in Timely Analysis, Weekend Blitz | Tagged , , , , , , , , , | Leave a comment

Why Nuplazid Alzheimer’s Data Is Great for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Owners, & Acquirers

Some are criticizing Phase 2 Nuplazid data on ADP, but we believe the implications for ACAD stock are much greater than most realize.

Posted in Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , | Leave a comment